4,552 publications from this institution
Background To identify an economical and effective antiviral agent we are nurturing chloroquine (CQ) which is an antiviral agent with multimodal and immune modalatory actions. Earlier studies have reported inhibition of HIV by CQ through its anti-integrase activity and also had elucidated that CQ inhibits HIV by inhibiting glycosylation of envelope glycoprotein. It had also been shown that CQ blocked Tumor-Necrosis-Factor (TNF-) alpha and Interleukin-6(IL-6); production and interferes with HIV replication.
Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Abstract Review: 291 refs.
Human cytomegalovirus (HCMV) infections are usually benign and self-limiting in the immunocompetent population; however, HCMV is a well-recognized problem among immunocompromised patients (in particular immunosuppressed patients with stem cell or solid organ transplantation, AIDS, or cancer). In this group of patients, HCMV infections are a significant cause of morbidity and mortality. Additionally, congenital HCMV infections are a leading cause of birth defects and infections in children, occurring in 1 to 2% of all live births. Currently available drugs for the treatment of HCMV diseases in the immunocompromised host include ganciclovir (GCV), its oral prodrug valganciclovir (VGCV), cidofovir (CDV), foscavir (FOS), and fomivirsen. Except for fomivirsen, all these drugs are targeted at the viral DNA polymerase. Even if presently approved anti-HCMV drugs have considerable helped in the management of HCMV disease in the immunocompromised host, their use is limited due to questions of toxicity, poor oral bioavailability, modest efficacy, and development of virus-drug resistance. Furthermore, no drug has been licensed to treat congenital HCMV. For these reasons, there is a real need to develop new compounds active against HCMV. The search for novel inhibitors of HCMV replication has led to the identification of new molecular viral targets such as the protein kinase UL97 and proteins involved in genome replication or in viral maturation and egress. Moreover, a new strategy based on the identification of specific cellular targets required for viral replication has been developed. This review will focus on new compounds that inhibit a specific viral process (viral targets) and on cell-based approaches (cellular targets) that result in selective inhibition of virus replication.
No abstract is provided for this article.
D-Eritadenine ( Ia ) and L-eritadenine ( IIa ) were prepared from 5-(adenin-9-yl)-5-deoxyaldofuranoses or enantiomeric 2,3-disubstituted erythronolactones ( VIIIb, c, XIV ). Oxidation of methyl 2,3-O-isopropylidene-D-ribofuranoside ( IX ) with periodate in the presence of ruthenium, followed by acid hydrolysis and reduction with sodium borohydride, afforded L-ribonolactone ( XI ). Its 2,3-O-isopropylidene derivative was subjected to alkaline hydrolysis, followed by oxidation with periodate, reduction with sodium borohydride and reaction with cyclohexanone to give 2,3-O-cyclohexylidene-L-erythronolactone ( XIV ). Condensation of [U- 14 C]-adenine with VIIIb , followed by acid hydrolysis, afforded [U- 14 C-adenine]-D-eritadenine. The threo -eritadenines III and IV were prepared by oxidation of 1-(adenin-9-yl)-1-deoxy-2,3-O-isopropylidenethreitols XVI and XVII with sodium periodate in the presence of ruthenium, followed by acid hydrolysis. Reaction of 9-(2,2-diethoxyethyl)adenine ( XIX ) with malonic acid gave 4-(adenin-9-yl)-3-butenoic acid ( XXI ); its methyl ester XXII , prepared by treatment with methanol, was isomerized with triethylamine to give methyl 4-(adenin-9-yl)-2-butenoate ( XXIII ). Hydroxylation of XXIII with osmium tetroxide afforded the racemic mixture of D- and L- threo -eritadenine ( III + IV ). Eritadenines Ia and IIa were active against vaccinia, measles and vesicular stomatitis virus. Eritadenine Ia was also effective against reo- and parainfluenza virus. In general, the antiviral activity of the eritadenines decreased in the order D- erythro ( Ia ) > L- erythro ( IIa ) > D- and L- threo ( III, IV ).
Different treatment schedules have been investigated when evaluating the inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 3'-azido-2',3'-dideoxythymidine (AZT) on the replication of human immunodeficiency virus type I (HIV-I) in MT-4 cells, transformation of C3H/3T3 cells by Moloney murine sarcoma virus (MSV), and MSV-induced tumor formation in newborn NMRI mice. Shortening the exposure time of HIV-I-infected MT-4 cells to PMEA or AZT led to an increase in the selectivity index of both compounds. PMEA proved markedly more efficient in suppressing MSV-induced tumor formation in mice when administered as a single dose on the day of infection than when these doses were spread over 2, 4 or 7 administrations within 1 week after the virus infection. This was not observed when the total dose of AZT was fractionated. While the infrequent dosage regimen increased the anti-retrovirus activity of PMEA, it did not increase its toxicity for the host. This unique property makes PMEA an attractive candidate for the treatment of retrovirus infections, including AIDS.